Check-Cap (Check-Cap) Short Percentage of Float

View and export this data going back to 2015. Start your Free Trial

What is Check-Cap Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Check-Cap's Short Percentage of Float

For the Diagnostics & Research subindustry, Check-Cap's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Check-Cap's Short Percentage of Float Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Check-Cap's Short Percentage of Float falls into.

Check-Cap (Check-Cap) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (NAS:CHEK) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

7CC:Germany

Address

29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000

Website

https://www.check-cap.com

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.